Hikma Pharmaceuticals PLC 2024 AR2
The report highlights Hikma's strong performance in 2024, with Group core revenue growing 10% to $3,156 million and core operating profit increasing to $719 million. Key strategic milestones included the acquisition of Xellia Pharmaceuticals' US finished dosage form business and the signing of a significant new long-term contract manufacturing agreement in the Generics segment. In sustainability, the company achieved a 15% reduction in Scope 1 and 2 greenhouse gas emissions compared to its 2020 baseline and conducted a comprehensive double materiality assessment in preparation for CSRD compliance.
Company: Hikma Pharmaceuticals PLC
Sector: Health Care
Country: United Kingdom
Year: 2024
Type: AR2
Pages: 111
Hikma Pharmaceuticals PLC
Annual Report
The report highlights Hikma's strong performance in 2024, with Group core revenue growing 10% to $3,156 million and core operating profit increasing to $719 million. Key strategic milestones included the acquisition of Xellia Pharmaceuticals' US finished dosage form business and the signing of a significant new long-term contract manufacturing agreement in the Generics segment. In sustainability, the company achieved a 15% reduction in Scope 1 and 2 greenhouse gas emissions compared to its 2020 baseline and conducted a comprehensive double materiality assessment in preparation for CSRD compliance.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Women on Board
Women in Management
Net Zero Target
Employees